Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients With Mutations in the TK Domain of EGFR

• Status: Completed
• Trial end date: 2012-12-01

Summary

A Phase III, multicenter, open-label, randomized trial of Erlotinib (Tarceva®) versus chemotherapy in patients with advanced NSCLC with mutations in the Tyrosine Kinase (TK) domain of the EGFR.

• Phase: Phase 3

Details

• Lead Sponsor: Spanish Lung Cancer Group
• Treatments: Carboplatin; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Gemcitabine